Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder

被引:44
作者
Koran, Lorrin M. [1 ]
Aboujaoude, Elias [1 ]
Gamel, Nona N. [1 ]
机构
[1] Stanford Med Ctr, Dept Psychiat & Behav Sci, Stanford, CA USA
关键词
ADJUVANT BUSPIRONE; TREATED PATIENTS; AMPHETAMINE; ADDERALL; SCALE;
D O I
10.4088/JCP.08m04605
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: Two small, double-blind, placebo-controlled, single-dose, crossover studies found dextroamphetamine (d-amphetamine) 30 mg clearly superior to placebo in relieving symptoms of obsessive-compulsive disorder (OCD). We conducted a 5-week, double-blind, caffeine-controlled study to test the hypothesis that d-amphetamine, added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity. Method: Between August 2006 and February 2008, we enrolled adults with DSM-IV OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >= 20 after >= 12 weeks of adequate treatment with an SSRI or SNRI. Subjects were randomly assigned to double-blind d-amphetamine 30 mg/d or caffeine 300 mg/d added to their SSRI/SNRI and other medications. Responders (first week mean Y-BOCS score decrease of >= 20%) entered the study's 4-week double-blind extension phase. Results: We enrolled 24 subjects, 11 women and 13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n = 12) and 29.1 (4.0) for the caffeine group (n = 12). At the end of week 1, 6 of 12 cl-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders' mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%-80%); and, for the caffeine group, 55% (range, 27%-89%). Obsessive-compulsive disorder and depression improvement were independent. The double-blind remained intact. No subject discontinued the study due to side effects. Conclusions: Larger, double-blind, placebo-controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inadequately responsive to adequate doses of an SSRI or SNRI.
引用
收藏
页码:1530 / 1535
页数:6
相关论文
共 29 条
[1]   Adderall for obsessive-compulsive disorder [J].
Albucher, RC ;
Curtis, GC .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (05) :818-819
[2]  
Arnsten AFT, 2006, J CLIN PSYCHIAT, V67, P7
[3]   A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder [J].
Bloch, M. H. ;
Landeros-Weisenberger, A. ;
Kelmendi, B. ;
Coric, V. ;
Bracken, M. B. ;
Leckman, J. F. .
MOLECULAR PSYCHIATRY, 2006, 11 (07) :622-632
[4]   Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users [J].
Childs, E ;
de Wit, H .
PSYCHOPHARMACOLOGY, 2006, 185 (04) :514-523
[5]  
Donovan J L, 2001, Psychopharmacol Bull, V35, P30
[6]   Dopamine transporter genotype influences the physiological response to medication in ADHD [J].
Gilbert, Donald L. ;
Wang, Zhewu ;
Sallee, Floyd R. ;
Ridel, Keith R. ;
Merhar, Stephanie ;
Zhang, Jie ;
Lipps, Tara D. ;
White, Colin ;
Badreldin, Nevert ;
Wassermann, Eric M. .
BRAIN, 2006, 129 :2038-2046
[7]  
GOLDSTEIN A, 1965, J PHARMACOL EXP THER, V150, P146
[8]  
GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
[9]  
GRADY TA, 1993, AM J PSYCHIAT, V150, P819
[10]  
GUY W, 1976, ASSESSMENT MANUAL PS, P218